M. Lahfa

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich et al. · Archives of Dermatological Research · 2010 · 868 citations · Full text

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

Kim Papp, Stephen K. Tyring, M. Lahfa et al. · British Journal of Dermatology · 2005 · 687 citations

Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial

Thomas Ruzicka, Charles Lynde, Gregor B. E. Jemec et al. · British Journal of Dermatology · 2008 · 399 citations

Severe Che Refractory, Ophthalmology, Atopic Dermatitis +10

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

Sakari Reitamo, Malcolm H.A. Rustin, Thomas Ruzicka et al. · Journal of Allergy and Clinical Immunology · 2002 · 256 citations · Full text

Atopic Dermatitis, Dermatology, Hydrocortisone Butyrate Ointment +3

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension

P.C.M. van de Kerkhof, Siegfried Segaert, M. Lahfa et al. · British Journal of Dermatology · 2008 · 177 citations